Last updated: September 2, 2026
Phendimetrazine is an off-patent, Schedule III sympathomimetic anorectic marketed primarily as phendimetrazine tartrate in 35 mg immediate-release tablets and 105 mg extended-release capsules. The commercial opportunity is not patent exclusivity. It is formulation execution: reliable modified release, controlled-substance manufacturing, supply continuity, differentiated packaging, and cost-efficient products for a mature generic market.
The most defensible excipient strategy is to maintain a simple immediate-release tablet platform while developing a robust extended-release multiparticulate or matrix capsule with demonstrated resistance to alcohol-induced dose dumping. Any new product must manage abuse potential, dissolution variability, stability, excipient compatibility, and FDA controlled-substance requirements.
What is phendimetrazine and how is it regulated?
Phendimetrazine tartrate is an anorectic agent indicated as a short-term adjunct to caloric restriction and behavioral modification for weight reduction in patients with an initial body mass index meeting the labeled criteria. FDA labeling limits treatment to short-term use, generally interpreted as a few weeks, rather than chronic obesity management.[1]
| Attribute |
Phendimetrazine |
| Active moiety |
Phendimetrazine |
| Common pharmaceutical form |
Phendimetrazine tartrate |
| Immediate-release strength |
35 mg |
| Extended-release strength |
105 mg |
| Therapeutic category |
Sympathomimetic anorectic |
| FDA controlled-substance schedule |
Schedule III |
| Typical dosage forms |
Tablet and extended-release capsule |
| Reference products |
Bontril PDM and Bontril SR |
| Regulatory pathway for generics |
Abbreviated New Drug Application |
| Biosimilar relevance |
None; phendimetrazine is a small molecule |
| Current exclusivity opportunity |
No meaningful branded exclusivity expected |
Phendimetrazine is chemically related to sympathomimetic stimulants and is subject to controlled-substance controls. The FDA-approved labeling warns against use in patients with cardiovascular disease, uncontrolled hypertension, hyperthyroidism, glaucoma, agitation, or a history of drug abuse.[1]
What formulations are protected by phendimetrazine patents?
The principal commercial formulations are immediate-release 35 mg tablets and extended-release 105 mg capsules. The relevant formulation concepts are old and do not appear to create a significant current patent barrier.
| Formulation |
Commercial role |
Likely IP position |
Commercial implication |
| 35 mg immediate-release tablet |
Standard generic product |
Historical patents expired or commercially irrelevant |
Low technical entry barrier |
| 105 mg extended-release capsule |
Once-daily modified-release product |
Historical formulation protection is unlikely to block entry |
Higher development and bioequivalence burden |
| Tartrate salt |
Standard active form |
Old salt and composition rights are expected to be expired |
No meaningful salt-based exclusivity |
| Multiparticulate capsule |
Potential modern platform |
New patentability depends on genuinely differentiated release or abuse-deterrent technology |
Possible niche protection, but limited market size |
| Abuse-deterrent formulation |
Potential lifecycle product |
Could support new patent claims if technically distinctive |
Commercial value depends on payer and regulatory acceptance |
The primary opportunity is therefore not freedom to practice a current branded patent estate. It is the creation of a technically differentiated product that may support a new formulation patent, provided the product demonstrates a non-obvious performance advantage.
When does phendimetrazine lose exclusivity?
Phendimetrazine lost effective market exclusivity decades ago. The active ingredient was introduced long before the modern Hatch-Waxman framework, and current products are marketed in a mature generic environment.
The practical exclusivity position is:
- No expected active-ingredient patent barrier.
- No biosimilar exclusivity issue.
- No meaningful orphan-drug exclusivity.
- No expected five-year new chemical entity exclusivity for current products.
- No material branded exclusivity for standard 35 mg tablets or 105 mg extended-release capsules.
- Generic entry is primarily constrained by ANDA approval, controlled-substance quotas, manufacturing capacity, and commercial economics.
A sponsor should verify the current Orange Book and FDA approval records before filing. The absence of a meaningful patent barrier does not eliminate the need to review listed patents, pediatric exclusivity, labeling carve-outs, and any product-specific litigation record.[2]
What is the Orange Book status of phendimetrazine?
Phendimetrazine products are evaluated through FDA-approved product records and generic approvals. Orange Book analysis should focus on the specific reference-listed drug, dosage form, strength, and route rather than on the active ingredient generally.
For a diligence review, the relevant questions are:
- Which product is designated as the reference-listed drug for the proposed 35 mg tablet or 105 mg extended-release capsule?
- Are any patents currently listed against that reference product?
- Does the proposed labeling require a Paragraph IV certification or a Section viii statement?
- Are there approved ANDAs for the exact dosage form and strength?
- Are any products currently discontinued, in shortage, or commercially unavailable?
Because phendimetrazine products have had multiple manufacturers and product histories, regulatory status should be confirmed product by product in the FDA Orange Book and Drugs@FDA databases.[2,3]
How should excipients be selected for phendimetrazine tablets?
A 35 mg immediate-release tablet offers the lowest-cost development path. The formulation objective is rapid, reproducible release without unnecessary excipient complexity.
Recommended immediate-release platform
A conventional direct-compression or wet-granulated tablet may use:
- Microcrystalline cellulose as a diluent and compressibility aid.
- Lactose monohydrate or dibasic calcium phosphate as a secondary filler.
- Crospovidone, croscarmellose sodium, or sodium starch glycolate as a disintegrant.
- Povidone or pregelatinized starch as a binder.
- Colloidal silicon dioxide as a glidant.
- Magnesium stearate or sodium stearyl fumarate as a lubricant.
- Film coating based on hypromellose, polyethylene glycol, titanium dioxide, and permitted colorants.
The selection should be driven by dissolution performance, tablet robustness, moisture sensitivity, and the inactive-ingredient precedents recorded in FDA's Inactive Ingredient Database.[4]
Key immediate-release risks
Phendimetrazine tartrate is a potent active at the labeled dose, so content uniformity is central. The formulation should be assessed for:
- Low-dose blend segregation.
- Lubricant overmixing and dissolution slowdown.
- Moisture-driven tablet softening or degradation.
- Tartrate salt compatibility with alkaline excipients.
- Colorant and coating variability.
- Extractables and leachables from high-barrier packaging.
A simple formulation may be commercially superior to a complex one because the product has limited pricing power. The target should be a robust, low-cost tablet with standard excipients that have broad FDA precedent.
What excipients are suitable for extended-release phendimetrazine?
The 105 mg extended-release capsule presents the more attractive technical opportunity. The product requires controlled release over the dosing interval while limiting the risk of rapid release after mechanical manipulation or exposure to alcohol.
Multiparticulate capsule strategy
A multiparticulate design can use coated pellets or granules filled into a hard gelatin or hydroxypropyl methylcellulose capsule. Potential functional excipients include:
- Sugar spheres or microcrystalline cellulose starter cores.
- Povidone or hydroxypropyl cellulose as a binder.
- Ethylcellulose as a water-insoluble rate-controlling polymer.
- Hypromellose as a pore-forming or release-modifying polymer.
- Polyethylene glycol or triethyl citrate as a plasticizer.
- Talc or colloidal silicon dioxide as an anti-tacking agent.
- Functional coating layers to separate the drug from the release-control membrane.
Multiparticulates can reduce the effect of localized manufacturing defects and offer more predictable gastrointestinal distribution than a single monolithic matrix. They also permit release tuning through pellet coating weight, polymer grade, pore former concentration, and capsule fill composition.
Hydrophilic matrix strategy
A hydrophilic matrix tablet or capsule can use:
- Hypromellose at a selected viscosity grade.
- Polyethylene oxide for stronger gel formation.
- Microcrystalline cellulose or lactose as a filler.
- Colloidal silicon dioxide for flow.
- Magnesium stearate or sodium stearyl fumarate as lubricant.
This approach is less complex than multiparticulates but may be more sensitive to tablet geometry, compression force, gastrointestinal agitation, and dose dumping. It may also be harder to match an existing reference product if the reference uses a multiparticulate system.
Excipient decision matrix
| Objective |
Preferred excipient or platform |
Main risk |
| Low-cost immediate release |
Microcrystalline cellulose plus superdisintegrant |
Blend uniformity and lubricant sensitivity |
| Extended release with flexible tuning |
Ethylcellulose-coated multiparticulates |
Coating uniformity and scale-up |
| Extended release with simple manufacturing |
Hypromellose matrix |
Food and agitation sensitivity |
| Moisture protection |
High-barrier blister or HDPE bottle with desiccant |
Packaging cost |
| Abuse resistance |
Robust multiparticulate membrane or polymer matrix |
Bioequivalence and patient acceptability |
| Capsule-shell compatibility |
Gelatin or HPMC shell selected through stability studies |
Moisture transfer and brittleness |
What bioequivalence and dissolution requirements affect commercial entry?
For an immediate-release generic, the central development burden is comparative bioavailability, dissolution similarity, assay, content uniformity, and stability. For an extended-release product, the burden is higher because the sponsor must reproduce the reference product's release profile and pharmacokinetic behavior.
The development program should include:
- Comparative fasting and fed pharmacokinetic studies.
- Multiple dissolution media and agitation conditions.
- Alcohol-induced dose-dumping studies.
- Discriminating dissolution methods for formulation changes.
- In vitro-in vivo correlation assessment where useful.
- Stability studies in final commercial packaging.
- Evaluation of capsule opening or sprinkling only if the proposed labeling supports it.
- In-process controls for pellet coating weight gain, particle-size distribution, and capsule fill weight.
For controlled-release products, a formulation that passes a single dissolution method but fails under alcohol exposure or mechanical stress may create a regulatory and product-liability problem. Release specifications should be designed to detect coating defects, polymer variability, and scale-up drift.
Which companies are challenging the phendimetrazine market?
The market is primarily generic and has historically included multiple manufacturers and labelers. Competitive participation can change because of controlled-substance quotas, low reimbursement, manufacturing decisions, and product discontinuations.
The relevant competitor groups are:
- Established generic companies supplying 35 mg tablets.
- Specialty manufacturers supplying extended-release capsules.
- Contract manufacturers with controlled-substance handling capability.
- Pharmacy suppliers and distributors managing short-term supply.
- Potential 505(b)(2) developers pursuing modified-release or abuse-deterrent products.
The commercial field is less attractive for a broad product launch than for a focused supply strategy. A manufacturer with reliable availability, competitive pricing, and both tablet and extended-release presentations can gain share when competitors experience manufacturing interruptions.
What generic entry risks exist for phendimetrazine?
Generic entry risk is high for the incumbent because the products are mature and standard formulations are readily substitutable. For a new entrant, the principal risks are economic and regulatory rather than patent-related.
| Risk |
Assessment |
Impact |
| Patent challenge |
Low for standard products |
Limited legal barrier |
| ANDA competition |
High |
Price erosion |
| Controlled-substance quota |
Moderate to high |
Limits production and inventory |
| Extended-release bioequivalence |
Moderate to high |
Longer development timeline |
| Supply-chain disruption |
Moderate |
Creates opportunity but increases execution risk |
| Abuse and diversion concerns |
High |
Packaging and distribution controls required |
| Reimbursement pressure |
High |
Favors low-cost manufacturing |
| Market size |
Limited |
Restricts return on complex formulation investment |
A generic launch scenario for the 35 mg tablet is likely to involve rapid price competition. The 105 mg extended-release capsule may offer better margin protection because fewer suppliers may be willing to absorb the development and manufacturing burden.
How strong is the phendimetrazine patent estate?
The patent estate is weak as a barrier to standard generic entry. Any defensible new patent position would need to arise from a specific formulation, manufacturing method, abuse-deterrent feature, or clinically relevant dosing profile.
Potential claim areas include:
- Defined polymer ratios producing a reproducible release profile.
- Alcohol-resistant extended-release pellets.
- A capsule with a specified release-control coating architecture.
- Low-moisture manufacturing and packaging processes.
- A formulation that reduces peak concentration while maintaining exposure.
- A sprinkle-compatible multiparticulate dosage form.
- A stability advantage linked to a specific excipient combination.
Patent value would depend on technical evidence. Broad claims covering phendimetrazine plus conventional excipients would face substantial validity and obviousness risk.
What manufacturing and intellectual-property barriers apply?
Controlled-substance manufacturing is the most important operational barrier. A sponsor needs compliant procurement, storage, batch reconciliation, security, recordkeeping, and quota management under Drug Enforcement Administration requirements.[5]
Extended-release manufacture adds:
- Uniform coating of drug-loaded pellets.
- Tight control of polymer viscosity and coating dispersion.
- Environmental control for humidity and temperature.
- Validated cleaning procedures to prevent cross-contamination.
- Specialized dissolution testing.
- Packaging that limits moisture ingress.
- Batch-to-batch control of capsule fill weight and pellet distribution.
A contract development and manufacturing organization with existing Schedule III capability may reduce launch time. A company without controlled-substance infrastructure faces higher fixed costs and regulatory complexity.
What licensing deals could create value?
Traditional licensing economics are limited because the active ingredient is generic. Value may arise from licensing a platform rather than the molecule.
Potential transactions include:
- Licensing an extended-release multiparticulate technology.
- Acquiring an ANDA or discontinued product with established reference-product status.
- Contract manufacturing and supply agreements for the 105 mg capsule.
- Licensing abuse-deterrent technology.
- Regional commercialization rights where supply is fragmented.
- Co-development agreements tied to obesity or appetite-control combinations.
A license should be evaluated against the small addressable market and expected generic price erosion. Royalty-bearing rights to a conventional tablet formulation are unlikely to be attractive unless they include manufacturing capacity, an approved ANDA, or a differentiated supply position.
How does phendimetrazine compare with competing weight-loss drugs?
Phendimetrazine competes against older sympathomimetics such as phentermine and diethylpropion, but it does not compete on equal commercial terms with newer chronic obesity therapies such as GLP-1 receptor agonists.
| Product class |
Typical use |
Patent position |
Commercial profile |
| Phendimetrazine |
Short-term appetite suppression |
Mature generic |
Low-cost, limited-duration therapy |
| Phentermine |
Short-term appetite suppression |
Mature generic |
Larger generic presence |
| Diethylpropion |
Short-term appetite suppression |
Mature generic |
Smaller niche |
| Naltrexone/bupropion |
Chronic weight management |
Product-specific patents may apply |
Higher-cost branded/generic competition |
| GLP-1 receptor agonists |
Chronic weight management and diabetes |
Active or recently active major estates |
High-value, clinically differentiated market |
Phendimetrazine's commercial advantage is price. Its disadvantage is the short-term label, stimulant-related safety profile, and limited differentiation from other low-cost anorectics.[1,6]
What FDA and commercial pathway is most attractive?
The lowest-risk route is an ANDA for a standard 35 mg immediate-release tablet, assuming an appropriate reference-listed drug and available product-specific regulatory pathway. The higher-value route is an ANDA for the 105 mg extended-release capsule, but it requires stronger formulation capability and more extensive comparative testing.
A 505(b)(2) strategy could support a modified-release, abuse-deterrent, or alternate-delivery product. Its commercial viability would depend on clinical differentiation, payer coverage, and whether the formulation solves a recognized problem. A new excipient combination alone is unlikely to justify substantial premium pricing.
Key Takeaways
- Phendimetrazine is an old, generic, Schedule III anorectic marketed mainly as phendimetrazine tartrate.
- The 35 mg immediate-release tablet is a low-barrier, price-sensitive opportunity.
- The 105 mg extended-release capsule offers greater formulation and supply-chain differentiation.
- Multiparticulate ethylcellulose or hydrophilic hypromellose systems are the most credible extended-release platforms.
- Alcohol-induced dose dumping, content uniformity, and controlled-substance manufacturing are key development risks.
- Standard phendimetrazine products have weak patent protection and no biosimilar issue.
- A new patent position would need to rest on a technically differentiated formulation or manufacturing process.
- Commercial returns are more likely from supply reliability, an approved ANDA, or regional distribution rights than from conventional excipient innovation.
- Licensing value is highest when tied to a formulation platform, controlled-substance manufacturing capacity, or an existing regulatory asset.
FAQs
Is phendimetrazine tartrate the same as phendimetrazine?
Phendimetrazine tartrate is the salt form used in marketed pharmaceutical products. Label strengths are expressed as phendimetrazine tartrate, while pharmacologic activity is associated with the phendimetrazine moiety.
Can phendimetrazine be formulated as a once-daily product?
Yes. The 105 mg extended-release capsule is designed for once-daily administration under approved labeling. Any new once-daily product must demonstrate comparable release and pharmacokinetic performance.
Are there abuse-deterrent opportunities for phendimetrazine?
Potentially, but the commercial case is uncertain. A formulation would need to show meaningful resistance to crushing, extraction, manipulation, or alcohol-triggered dose dumping and would require regulatory and market evidence to support premium pricing.
Does phendimetrazine have biosimilar competition?
No. Phendimetrazine is a small-molecule drug. Competition occurs through generic drug applications rather than the biosimilar pathway.
Which phendimetrazine dosage form has the stronger commercial opportunity?
The 105 mg extended-release capsule has greater potential for differentiation because it requires more specialized formulation and manufacturing. The 35 mg tablet is easier to develop but faces stronger price competition.
References
-
U.S. Food and Drug Administration. (2010). Bontril PDM (phendimetrazine tartrate) tablets: Prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs. FDA.
-
U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. FDA.
-
U.S. Drug Enforcement Administration. (2024). Controlled substances regulations and requirements. U.S. Department of Justice.
-
National Institute of Diabetes and Digestive and Kidney Diseases. (2023). Prescription medications to treat overweight and obesity. National Institutes of Health.
